In another artificial intelligence (AI)-driven deal, Sanofi has paid Insilico Medicine US$21.5 M upfront and committed up to US$1.2 B more to enter into a multi-year strategic research collaboration to advance drug development candidates for up to six new targets. The alliance will grant Sanofi access to Insilico’s Pharma.AI suite which includes component platforms for next-generation drug development. In recent months, Sanofi has invested heavily in AI-based drug discovery, inking deals with Owkin, Exscientia, Atomwise and most recently, BioMed X.